Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030


The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *